In Vitro Based Approaches to Evaluate the Bioequivalence of Generic Rectal and Vaginal Products

Archived

Food and Drug Administration

View on Grants.gov 📝 Build a proposal template ★ Save

Description

The purpose of this funding opportunity is to support research and development that will characterize the specific and unique considerations relevant to evaluating the bioequivalence (BE) of rectal and vaginal (topical) drug products. A specific emphasis of this funding opportunity involves the development of biorelevant performance tests as a component of product characterization-based BE approaches.

Who can apply

  • Others

Contact

Shashi Malhotra <br/>Grants Management Specialist <br/>Phone 2404027592
shashi.malhotra@fda.hhs.gov

Key dates & funding
  • PostedJan 13, 2022
  • ClosesMar 31, 2022
  • Award floor$50,000
  • Award ceiling$1,000,000
  • Program funding$1,000,000
  • CFDA93.103
Categories
Consumer Protection Health Science and Technology and other Research and Development

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro